{"schema_version":"secwatch.filing_event.v1","accession":"0001851734-22-000600","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2022-10-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.405037+00:00","generated_at":"2026-06-23T04:19:12.182761+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ChromaDex expands Nestlé Health Science supply deal to supplements; Nestlé invests $5M","bullets":["New 5-year supply agreement gives Nestlé non-exclusive rights to sell Niagen in dietary supplements, medical nutrition, and functional foods.","Nestlé commits to initial $1.975M Niagen purchase in 2022; ChromaDex eligible for low-single-digit royalties and low-seven-figure milestone payments.","Nestlé purchases 3,816,794 shares of CDXC at ~$1.31/share for $5M in a registered direct offering.","Agreement expands prior 2018 deal; term automatically extends if minimum purchase met."],"urls":{"canonical":"https://secwatch.observer/filing/0001851734-22-000600","json":"https://secwatch.observer/filing/0001851734-22-000600.json","markdown":"https://secwatch.observer/filing/0001851734-22-000600.md","text":"https://secwatch.observer/filing/0001851734-22-000600.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000185173422000600/0001851734-22-000600-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000185173422000600/cdxc20221007_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T04:19:12.182761+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}